evaluating ipss-r and ipss-m in patients with hr-mds enrolled in stimulus-mds1 and stimulus-mds2
Published 1 year ago • 60 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
1:39
ipss-r vs ipss-m for mds
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
3:57
validation of the ipss-m risk stratification system in mds
-
2:23
benefits, applicability & uses of the ipss-m in mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
1:29:13
myelodysplastic syndrome
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
3:41
treatment of anemia in lr-mds: luspatercept and imetelstat
-
1:30
the prognostic value of patient-reported outcomes in mds
-
54:01
mds prognosis - understanding ipss and ipss-r scores 2018
-
2:06
outcomes & promising treatment options following hma failure in patients with hr-mds
-
2:27
milestone trial results: mrd response-adapted deferral of autosct in newly diagnosed myeloma
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
4:31
re-evaluating the use of iwg 2006 response criteria in mds
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
1:27
current diagnostic modalities for the identification of ptld
-
1:34
personalizing treatment of transfusion-dependent anemia in lr-mds
-
1:05
identifying residual lscs that may evade standard mrd monitoring & lead to relapse in aml
-
1:59
the optec study: evaluating outpatient step-up administration of teclistamab in pts with r/r myeloma